The effects of early pregnancy home-based combined exercise training on the TNF-α/IL-10 ratio in overweight pregnant women: a randomized controlled trial
摘要
We assessed the effect of home-based combined exercise training on the balance of tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in overweight pregnant women.
MethodsThirty overweight pregnant women were randomly assigned to either an exercise group (n = 16) or a control group (n = 14). The combined exercise training consisted of 18–20 weeks of home-based moderate-intensity aerobic, resistance, and stretching exercises, performed five days per week from 16–18 to 36–37 weeks of pregnancy. Measurements were taken at three time points, namely 16–18, 25–29, and 36–37 weeks of pregnancy. Five participants withdrew during the study. Furthermore, neonatal anthropometric measurements, including length, weight, head circumference, and chest circumference, were assessed one hour after birth.
ResultsData analysis indicated no significant difference between the two groups for IL-10 (p > 0.05), while a significant difference was observed for TNF-α in the second and third trimesters, with a greater reduction observed in the exercise group (p < 0.05). Additionally, the TNF-α/IL-10 ratio showed a significant difference in the third trimester but not in the second trimester (p < 0.05). Moreover, there were significant differences in physical fitness, including maximal voluntary contraction and the 6-min walk test (p < 0.05), with a greater decline observed in the control group. Finally, there were no significant differences in neonatal indicators (e.g., weight) between the two groups (p > 0.05).
ConclusionsHome-based combined exercise training may improve inflammatory status in overweight pregnant women during pregnancy. These findings support moderate-intensity exercise as a safe, feasible, non-pharmacological strategy to modulate pregnancy-related inflammation and promote maternal health.
Trial registrationThis trial was registered in the Iranian Registry of Clinical Trials (IRCT) with the code: IRCT20190410043222N1; date: 02.05.2019.